QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vir-biotechnology-doses-first-patient-in-phase-1-trial-of-dual-masked-t-cell-engager-vir-5500-for-prostate-cancer

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination wi...

 hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-15-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 p...

 evercore-isi-group-initiates-coverage-on-vir-biotechnology-with-outperform-rating-announces-price-target-of-12

Evercore ISI Group analyst Cory Kasimov initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Outperform rating and an...

 b-of-a-securities-upgrades-vir-biotechnology-to-buy-raises-price-target-to-14

B of A Securities analyst Geoff Meacham upgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Buy and raises the price tar...

 vir-biotechnology-q2-eps-080-misses-076-estimate-sales-121m-miss-238m-estimate

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(...

 vir-biotechnology-launches-final-eclipse-trial-advancing-full-registrational-program-for-chronic-hepatitis-delta

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3ECLIPSE 3 is designed ...

 vir-biotechnology-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-vir-5525-investigational-dual-masked-t-cell-engager-targeting-egfr

Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combina...

 raymond-james-initiates-coverage-on-vir-biotechnology-with-outperform-rating-announces-price-target-of-12

Raymond James analyst Sean McCutcheon initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Outperform rating and anno...

 needham-reiterates-buy-on-vir-biotechnology-maintains-14-price-target

Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $14 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION